LD-2 disclosure · 2nd Quarter - Report
NOVOCURE INC.
Client
- Name
- NOVOCURE INC.
- Description
- Commercial stage oncology dedicated to advancement of TTF therapy to treat solid tumors.
- Location
- New Hampshire · United States of America
Registrant
- Description
- Lobbying Law Firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesPharmacy
Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.
LobbyistsSUSAN HIRSCHMANN · ms MELINDA M MAXFIELD · DANIEL ZIEGLER · JEANNE HAGGERTY · mr JOSHUA DAVID FENDRICK · ROBERT BUTORA
Covered position (DANIEL ZIEGLER): Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn, Policy Director; Speaker Mike Johnson
Covered position (JEANNE HAGGERTY): Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
Covered position (mr JOSHUA DAVID FENDRICK): Staff Assistant, Legislative Correspondent, and Legislative Aide, Sen. Gary C. Peters; Economic Policy Adviser, Rep. Josh Gottheimer; Economic Policy Adviser, Sen. Gary C. Peters
Covered position (ROBERT BUTORA): Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.
LobbyistsSUSAN HIRSCHMANN · ms MELINDA M MAXFIELD · DANIEL ZIEGLER · JEANNE HAGGERTY · mr JOSHUA DAVID FENDRICK · ROBERT BUTORA